Royal Bank Of Canada Oncternal Therapeutics, Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.29 - $0.48 $2,530 - $4,188	8,726 Added 684.93%	10,000 $3,000
Q2 2023 Aug 14, 2023	BUY	$0.28 - $0.79 $356 - $1,006	1,274 New	1,274 $0
Q2 2022 Aug 15, 2022	SELL	$0.7 - $1.56 $1,903 - $4,241	-2,719 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.37 - $2.43 $8,702 - $15,435	-6,352 Reduced 70.03%	2,719 $4,000
Q4 2021 Feb 14, 2022	BUY	$2.27 - $4.39 $7,688 - $14,868	3,387 Added 59.59%	9,071 $21,000
Q3 2021 Nov 15, 2021	BUY	$3.37 - $4.76 $8,927 - $12,609	2,649 Added 87.28%	5,684 $23,000
Q2 2021 Aug 16, 2021	BUY	$4.75 - $9.39 $14,416 - $28,498	3,035 New	3,035 $14,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.